The Lupus Anticoagulant Paradox

Jessica E. Molhoek; Philip G. de Groot; Rolf T. Urbanus

doi:10.1055/s-0037-1606190

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2018; 44(05): 445-452
DOI: 10.1055/s-0037-1606190

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Lupus Anticoagulant Paradox

Jessica E. Molhoek

¹Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands

,

Philip G. de Groot

¹Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands

,

Rolf T. Urbanus

¹Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands

› Author Affiliations

Abstract

Lupus anticoagulant (LA) represents the most enigmatic antibody population in patients with antiphospholipid syndrome and represents a paradox that is still unsolved. This class of antiphospholipid antibody causes a phospholipid-dependent prolongation of the clotting time but is associated with an increased risk of thrombosis and pregnancy morbidity. In this review, we will provide an overview of the different antibodies that have been associated with LA activity, their importance based on clinical studies, and address the question why this prolongation of the clotting time is associated with thrombosis rather than a bleeding tendency.

Keywords

lupus anticoagulant - β2-glycoprotein I - prothrombin - antiphospholipid antibodies - thrombosis

Full Text

References

References
1 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
2 Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621-622
3 Ruffatti A, Del Ross T, Ciprian M. , et al; Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011; 70 (06) 1083-1086
4 Lockshin MD, Kim M, Laskin CA. , et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311-2318
5 Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost 2012; 38 (04) 385-389
6 Pennings MT, De Groot PG, Meijers JC, Huisman A, Derksen RH, Urbanus RT. Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma?. Thromb Haemost 2014; 112 (04) 736-742
7 Devreese KM, de Laat B. Mixing studies in lupus anticoagulant testing are required at least in some type of samples. J Thromb Haemost 2015; 13 (08) 1475-1478
8 Chandrashekar V. Dilute Russell's viper venom and activated partial thromboplastin time in lupus anticoagulant diagnosis: is mixing essential?. Blood Coagul Fibrinolysis 2016; 27 (04) 408-411
9 Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. ; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157 (01) 47-58
10 CLSI. Laboratory Testing for the Lupus Anticoagulant; Approved Guideline. CLSI Document H60-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2014
11 Triplett DA, Stocker KF, Unger GA, Barna LK. The textarin/ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993; 70 (06) 925-931
12 Rooney AM, McNally T, Mackie IJ, Machin SJ. The Taipan snake venom time: a new test for lupus anticoagulant. J Clin Pathol 1994; 47 (06) 497-501
13 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68 (04) 869-874
14 Pengo V, Tripodi A, Reber G. , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
15 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (05) 1827-1832
16 Naess IA, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006; 4 (01) 44-49
17 Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8 (11) 998-1005
18 de Groot PG, Urbanus RT. Antiphospholipid syndrome--not a noninflammatory disease. Semin Thromb Hemost 2015; 41 (06) 607-614
19 Yelnik CM, Laskin CA, Porter TF. , et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med 2016; 3 (01) e000131
20 Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010; 376 (9757): 2032-2039
21 Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013; 122 (05) 817-824
22 van Os GM, de Laat B, Kamphuisen PW, Meijers JC, de Groot PG. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 2011; 9 (08) 1657-1659
23 Kaushansky K, Lichtman MA, Prchal JT. , et al, eds. Williams Hematology, 9th ed. New York, NY: McGraw-Hill Education; 2016
24 Loeliger A. Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus?. Thromb Diath Haemorrh 1959; 3: 237
25 Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72 (02) 512-519
26 Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983; 61 (04) 684-692
27 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66 (06) 629-632
28 Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102 (08) 2717-2723
29 de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005; 3 (09) 1993-1997
30 Nojima J, Iwatani Y, Suehisa E, Kuratsune H, Kanakura Y. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica 2006; 91 (05) 699-702
31 Forastiero R, Martinuzzo M, Pombo G. , et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3 (06) 1231-1238
32 Amengual O, Forastiero R, Sugiura-Ogasawara M. , et al. Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus 2017; 26 (03) 266-276
33 Pengo V, Denas G, Bison E. , et al; Italian Federation of Thrombosis Centers (FCSA). Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with lupus anticoagulant (LA). Thromb Res 2010; 126 (02) 150-153
34 de Mast Q, Molhoek JE, van der Ven AJ. , et al. Antiphospholipid antibodies and the risk of stroke in urban and rural Tanzania: a community-based case-control study. Stroke 2016; 47 (10) 2589-2595
35 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87 (11) 4120-4124
36 Galli M, Comfurius P, Maassen C. , et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335 (8705): 1544-1547
37 Oosting JD, Derksen RH, Entjes HT, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost 1992; 67 (05) 499-502
38 Roubey RA, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992; 90 (03) 1100-1104
39 Pennings MT, van Lummel M, Derksen RH. , et al. Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost 2006; 4 (08) 1680-1690
40 Balasubramanian K, Schroit AJ. Characterization of phosphatidylserine-dependent beta2-glycoprotein I macrophage interactions. Implications for apoptotic cell clearance by phagocytes. J Biol Chem 1998; 273 (44) 29272-29277
41 Takeuchi R, Atsumi T, Ieko M. , et al. Coagulation and fibrinolytic activities in 2 siblings with beta(2)-glycoprotein I deficiency. Blood 2000; 96 (04) 1594-1595
42 Robertson SA, Roberts CT, van Beijering E. , et al. Effect of beta2-glycoprotein I null mutation on reproductive outcome and antiphospholipid antibody-mediated pregnancy pathology in mice. Mol Hum Reprod 2004; 10 (06) 409-416
43 Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A 1993; 90 (06) 2141-2145
44 Hamdan R, Maiti SN, Schroit AJ. Interaction of beta2-glycoprotein 1 with phosphatidylserine-containing membranes: ligand-dependent conformational alterations initiate bivalent binding. Biochemistry 2007; 46 (37) 10612-10620
45 Bouma B, de Groot PG, van den Elsen JM. , et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18 (19) 5166-5174
46 Willems GM, Janssen MP, Pelsers MM. , et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35 (43) 13833-13842
47 Galli M, Comfurius P, Barbui T, Zwaal RF, Bevers EM. Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68 (03) 297-300
48 Horbach DA, van Oort E, Derksen RH, de Groot PG. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity–discrimination between functional and non-functional anti-prothrombin-antibodies. Thromb Haemost 1998; 79 (04) 790-795
49 Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86 (02) 617-623
50 Simmelink MJ, Derksen RH, Arnout J, De Groot PG. A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003; 1 (04) 740-747
51 de Laat H, Derksen R, Urbanus R, Roest M, de Groot P. Beta(2)-glycoprotein I dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104 (12) 3598-3602
52 Pengo V, Brocco T, Biasiolo A, Rampazzo P, Carraro P, Zamarchi R. Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity. Blood 1999; 94 (11) 3814-3819
53 Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004; 2 (05) 702-707
54 Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost 1989; 62 (03) 892-896
55 Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993; 70 (05) 787-793
56 Jouhet J. Importance of the hexagonal lipid phase in biological membrane organization. Front Plant Sci 2013; 4: 494
57 Rauch J, Tannenbaum M, Neville C, Fortin PR. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Thromb Haemost 1998; 80 (06) 936-941
58 Safa O, Crippa L, Della Valle P, Sabbadini MG, Viganò D'Angelo S, D'Angelo A. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome. Haematologica 1999; 84 (09) 829-838
59 Pengo V, Ruffatti A, Legnani C. , et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8 (02) 237-242
60 Pengo V, Ruffatti A, Legnani C. , et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118 (17) 4714-4718
61 Pengo V, Testa S, Martinelli I. , et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res 2015; 135 (01) 46-49
62 Fabris M, Giacomello R, Poz A. , et al. The introduction of anti-phosphatidylserine/prothrombin autoantibodies in the laboratory diagnostic process of anti-phospholipid antibody syndrome: 6 months of observation. Auto Immun Highlights 2014; 5 (02) 63-67
63 Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998; 79 (01) 79-86
64 Field SL, Hogg PJ, Daly EB. , et al. Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow. Blood 1999; 94 (10) 3421-3431
65 Field SL, Chesterman CN, Dai YP, Hogg PJ. Lupus antibody bivalency is required to enhance prothrombin binding to phospholipid. J Immunol 2001; 166 (10) 6118-6125
66 Willems GM, Janssen MP, Comfurius P, Galli M, Zwaal RF, Bevers EM. Kinetics of prothrombin-mediated binding of lupus anticoagulant antibodies to phosphatidylserine-containing phospholipid membranes: an ellipsometric study. Biochemistry 2002; 41 (48) 14357-14363
67 Simmelink MJ, Horbach DA, Derksen RH. , et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 2001; 113 (03) 621-629
68 Pengo V, Thiagarajan P, Shapiro SS, Heine MJ. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987; 70 (01) 69-76
69 Breckenridge RT, Ratnoff OD. Studies on the site of action of a circulating anticoagulant in disseminated lupus erythematosus. Evidence that this anticoagulant inhibits the reaction between activated stuart factor (factor X) and proaccelerin (factor V). Am J Med 1963; 35: 813-819
70 Molhoek JE, de Groot PG, Meijers JCM, Urbanus RT. Lupus anticoagulant activity can be explained by interference of anti-b2GPI antibodies with the prothrombinase complex. J Thromb Haemost 2015; 13 (S2): AS035
71 Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A 2013; 110 (44) 17838-17843
72 Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999; 93 (08) 2552-2558
73 de Laat B, Eckmann CM, van Schagen M, Meijer AB, Mertens K, van Mourik JA. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrinolysis 2008; 19 (08) 757-764
74 Salemink I, Blezer R, Willems GM, Galli M, Bevers E, Lindhout T. Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost 2000; 84 (04) 653-656